Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Equity researchers SVB Leerink released their fiscal 2024 earnings per share (EPS) estimates for shares of Ultragenyx Pharmaceutical in a report released Thursday, February 10. . SVB Leerink analyst J. Schwartz expects the biopharmaceutical company to post earnings of ($4.62) per share for the year. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) last reported quarterly earnings data on Thursday, February 10. The biopharmaceutical company reported ($1.79) EPS for the quarter, missing the consensus estimate of ($1.32) by ($0.47). Ultragenyx Pharmaceutical posted a negative return on equity of 38.25% and a negative net margin of 98.89%. The company posted revenue of $83.39 million for the quarter, versus analyst estimates of $83.68 million. During the same period last year, the company achieved EPS of ($1.34). The company’s quarterly revenue was down 8.9% from the same quarter last year.
A number of other equity research analysts have also recently commented on the company. Morgan Stanley lowered its target price on Ultragenyx Pharmaceutical from $120.00 to $118.00 and set an “overweight” rating on the stock in a research note on Friday. JPMorgan Chase & Co. upgraded Ultragenyx Pharmaceutical from a “neutral” rating to an “overweight” rating and set a price target of $132.00 for the stock in a research report on Friday. Finally, Zacks Investment Research downgraded Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating and set a price target of $77.00 for the stock. in a Wednesday, January 12 research report. Two investment analysts gave the stock a sell rating, two gave the company a hold rating and ten gave the company a buy rating. Based on data from MarketBeat.com, Ultragenyx Pharmaceutical currently has a consensus rating of “Buy” and a consensus target price of $127.70.
RARE opened at $72.91 on Monday. The company has a market capitalization of $4.97 billion, a price-earnings ratio of -13.78 and a beta of 1.69. The company’s fifty-day moving average price is $76.11 and its two-hundred-day moving average price is $82.94. Ultragenyx Pharmaceutical has a 1-year low of $62.37 and a 1-year high of $155.76.
In other Ultranyx Pharmaceutical news, EVP Camille L. Bedrosian sold 1,657 shares of the company in a transaction that took place on Sunday, January 30. The stock was sold at an average price of $66.30, for a total value of $109,859.10. The sale was disclosed in a filing with the Securities & Exchange Commission, accessible via this hyperlink. Insiders hold 6.70% of the shares of the company.
A number of institutional investors and hedge funds have recently bought and sold shares of RARE. Itau Unibanco Holding SA purchased a new equity stake in Ultragenyx Pharmaceutical during the second quarter at a value of $29,000. Dark Forest Capital Management LP bought a new position in Ultragenyx Pharmaceutical in the second quarter worth around $35,000. Benjamin F. Edwards & Company Inc. bought a new position in shares of Ultragenyx Pharmaceutical in the third quarter for a value of approximately $66,000. Advisor Group Holdings Inc. increased its stake in shares of Ultragenyx Pharmaceutical by 26.6% in the third quarter. Advisor Group Holdings Inc. now owns 1,612 shares of the biopharmaceutical company worth $146,000 after buying 339 additional shares during the period. Finally, the Canada Pension Plan Investment Board increased its stake in shares of Ultragenyx Pharmaceutical by 27.3% in the second quarter. The Canada Pension Plan Investment Board now owns 1,922 shares of the biopharmaceutical company worth $183,000 after buying 412 additional shares during the period. Institutional investors and hedge funds hold 96.91% of the company’s shares.
About Ultranyx Pharmaceutical
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company engaged in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. Mepsevii is an intravenous used for the treatment of mucopolysaccharidosis VII.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Ultragenyx Pharmaceutical right now?
Before you consider Ultragenyx Pharmaceutical, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and Ultragenyx Pharmaceutical didn’t make the list.
Although Ultragenyx Pharmaceutical currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here